[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Bevacizumab Biosimilar-Global Market Status and Trend Report 2013-2023

November 2017 | 154 pages | ID: B3AF1B11FFFEN
MIReports Co., Limited

US$ 2,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

Bevacizumab Biosimilar-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bevacizumab Biosimilar industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Bevacizumab Biosimilar 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Bevacizumab Biosimilar worldwide, with company and product introduction, position in the Bevacizumab Biosimilar market
Market status and development trend of Bevacizumab Biosimilar by types and applications
Cost and profit status of Bevacizumab Biosimilar, and marketing status
Market growth drivers and challenges

The report segments the global Bevacizumab Biosimilar market as:

Global Bevacizumab Biosimilar Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)

North America
Europe
China
Japan
Rest APAC
Latin America

Global Bevacizumab Biosimilar Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

100mg
400mg

Global Bevacizumab Biosimilar Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Colorectal cancer
Lung cancer
Breast cancer
Renal cancers
Brain cancers

Global Bevacizumab Biosimilar Market: Manufacturers Segment Analysis (Company and Product introduction, Bevacizumab Biosimilar Sales Volume, Revenue, Price and Gross Margin):

Pfizer
Allergan
Amgen
Biocon
Reliance lifesciences
Bevacizumab
Beaconpharma
Celgene Corporation
Fujifilm Kyowa Kirin Biologics
Hetero Drugs

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BEVACIZUMAB BIOSIMILAR

1.1 Definition of Bevacizumab Biosimilar in This Report
1.2 Commercial Types of Bevacizumab Biosimilar
  1.2.1 100mg
  1.2.2 400mg
1.3 Downstream Application of Bevacizumab Biosimilar
  1.3.1 Colorectal cancer
  1.3.2 Lung cancer
  1.3.3 Breast cancer
  1.3.4 Renal cancers
  1.3.5 Brain cancers
1.4 Development History of Bevacizumab Biosimilar
1.5 Market Status and Trend of Bevacizumab Biosimilar 2013-2023
  1.5.1 Global Bevacizumab Biosimilar Market Status and Trend 2013-2023
  1.5.2 Regional Bevacizumab Biosimilar Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Development of Bevacizumab Biosimilar 2013-2017
2.2 Production Market of Bevacizumab Biosimilar by Regions
  2.2.1 Production Volume of Bevacizumab Biosimilar by Regions
  2.2.2 Production Value of Bevacizumab Biosimilar by Regions
2.3 Demand Market of Bevacizumab Biosimilar by Regions
2.4 Production and Demand Status of Bevacizumab Biosimilar by Regions
  2.4.1 Production and Demand Status of Bevacizumab Biosimilar by Regions 2013-2017
  2.4.2 Import and Export Status of Bevacizumab Biosimilar by Regions 2013-2017

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

3.1 Production Volume of Bevacizumab Biosimilar by Types
3.2 Production Value of Bevacizumab Biosimilar by Types
3.3 Market Forecast of Bevacizumab Biosimilar by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Bevacizumab Biosimilar by Downstream Industry
4.2 Market Forecast of Bevacizumab Biosimilar by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BEVACIZUMAB BIOSIMILAR

5.1 Global Economy Situation and Trend Overview
5.2 Bevacizumab Biosimilar Downstream Industry Situation and Trend Overview

CHAPTER 6 BEVACIZUMAB BIOSIMILAR MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

6.1 Production Volume of Bevacizumab Biosimilar by Major Manufacturers
6.2 Production Value of Bevacizumab Biosimilar by Major Manufacturers
6.3 Basic Information of Bevacizumab Biosimilar by Major Manufacturers
  6.3.1 Headquarters Location and Established Time of Bevacizumab Biosimilar Major Manufacturer
  6.3.2 Employees and Revenue Level of Bevacizumab Biosimilar Major Manufacturer
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 BEVACIZUMAB BIOSIMILAR MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Pfizer
  7.1.1 Company profile
  7.1.2 Representative Bevacizumab Biosimilar Product
  7.1.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Allergan
  7.2.1 Company profile
  7.2.2 Representative Bevacizumab Biosimilar Product
  7.2.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Allergan
7.3 Amgen
  7.3.1 Company profile
  7.3.2 Representative Bevacizumab Biosimilar Product
  7.3.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Amgen
7.4 Biocon
  7.4.1 Company profile
  7.4.2 Representative Bevacizumab Biosimilar Product
  7.4.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Biocon
7.5 Reliance lifesciences
  7.5.1 Company profile
  7.5.2 Representative Bevacizumab Biosimilar Product
  7.5.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Reliance lifesciences
7.6 Bevacizumab
  7.6.1 Company profile
  7.6.2 Representative Bevacizumab Biosimilar Product
  7.6.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Bevacizumab
7.7 Beaconpharma
  7.7.1 Company profile
  7.7.2 Representative Bevacizumab Biosimilar Product
  7.7.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Beaconpharma
7.8 Celgene Corporation
  7.8.1 Company profile
  7.8.2 Representative Bevacizumab Biosimilar Product
  7.8.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.9 Fujifilm Kyowa Kirin Biologics
  7.9.1 Company profile
  7.9.2 Representative Bevacizumab Biosimilar Product
  7.9.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Fujifilm Kyowa Kirin Biologics
7.10 Hetero Drugs
  7.10.1 Company profile
  7.10.2 Representative Bevacizumab Biosimilar Product
  7.10.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Hetero Drugs

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BEVACIZUMAB BIOSIMILAR

8.1 Industry Chain of Bevacizumab Biosimilar
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BEVACIZUMAB BIOSIMILAR

9.1 Cost Structure Analysis of Bevacizumab Biosimilar
9.2 Raw Materials Cost Analysis of Bevacizumab Biosimilar
9.3 Labor Cost Analysis of Bevacizumab Biosimilar
9.4 Manufacturing Expenses Analysis of Bevacizumab Biosimilar

CHAPTER 10 MARKETING STATUS ANALYSIS OF BEVACIZUMAB BIOSIMILAR

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference


More Publications